213
Volume 5, Issue 10: Special Issue
(EJAR)
ISSN: 2181-2020
MPHAPP
THE 6TH INTERNATIONAL SCIENTIFIC AND PRACTICAL
CONFERENCE
“
MODERN PHARMACEUTICS: ACTUAL
PROBLEMS AND PROSPECTS
”
TASHKENT, OCTOBER 17, 2025
in-academy.uz
THE MODERN MARKET OF TRANSDERMAL DRUG DELIVERY SYSTEMS:
ANALYSIS OF REGISTRIES OF THE REPUBLIC OF KAZAKHSTAN AND THE
EAEU
Sadvakas A.K.
Zhandabayeva M.A.
Kazakh national medical university named by S. D. Asfendiyarov,
Almaty city, Republic of Kazakhstan
e-mail: akniyetsadvakassova@gmail.com
https://doi.org/10.5281/zenodo.17332951
Relevance:
transdermal therapeutic systems (TTS) represent one of the most promising
directions in the development of dosage forms, as they enable controlled delivery of active substances
while bypassing the gastrointestinal tract and reducing the risk of adverse effects. In light of the
growing interest in innovative drug delivery technologies, analysis of the TTS market in the Republic
of Kazakhstan and the Eurasian Economic Union (EAEU) is of significant scientific and practical
importance.
Purpose of the study:
to examine the range and registration dynamics of transdermal drug
delivery systems in the Republic of Kazakhstan and the EAEU based on the analysis of official
registries.
Materials and methods:
the study involved the analysis of scientific publications indexed in
international databases such as PubMed, ScienceDirect, Elibrary, and Google Scholar, addressing the
use and development of transdermal therapeutic systems. In addition, marketing reports and statistical
reviews reflecting global TTS market trends were reviewed. Furthermore, data from the State Register
of Medicines of the Republic of Kazakhstan and the Unified Register of Medicines of the EAEU were
analyzed to determine the assortment of registered TTS, their distribution by manufacturing countries,
and therapeutic applications. Methods of content analysis, comparative and statistical analysis were
applied to ensure objectivity and comprehensiveness of the study.
Results:
the analysis of the State Register of Kazakhstan demonstrated that the total number of
registered medicinal products exceeds 6,900 items, of which less than 0.5% are represented by
transdermal systems. Within the TTS category, 18 products were identified, predominantly
manufactured abroad: Germany (33%), Switzerland (22%), and the USA (17%). The assortment
mainly includes nicotine replacement patches, analgesics (fentanyl), and hormonal preparations
(estrogen-progestogen systems). At present, domestic production of TTS in Kazakhstan is absent.
The study of the Unified Register of the EAEU revealed 41 TTS products, with leading positions held
by Russia (39%), Germany (24%), France (12%), and Switzerland (10%). Russian manufacturers are
actively expanding their portfolios of nicotine replacement and analgesic systems, reflecting the
growth of this segment in the domestic market. Comparative analysis indicated that the EAEU market
for TTS is largely oriented toward imported products and multinational companies; however, Russia
is gradually developing its own production base. For Kazakhstan, this presents significant potential
for localization and import substitution within the framework of strategic objectives for
pharmaceutical sector development.
Conclusions:
the market of transdermal therapeutic systems in Kazakhstan and the EAEU
demonstrates growth and increasing interest from both consumers and the medical community.
Despite the limited product range and dominance of foreign manufacturers, Kazakhstan possesses
prerequisites for the development of its own TTS production. The existing scientific and technical
214
Volume 5, Issue 10: Special Issue
(EJAR)
ISSN: 2181-2020
MPHAPP
THE 6TH INTERNATIONAL SCIENTIFIC AND PRACTICAL
CONFERENCE
“
MODERN PHARMACEUTICS: ACTUAL
PROBLEMS AND PROSPECTS
”
TASHKENT, OCTOBER 17, 2025
in-academy.uz
potential, pharmaceutical clusters, and government measures aimed at stimulating innovation create
favorable conditions for the introduction of this advanced dosage form. The establishment of
domestic TTS manufacturing will reduce dependence on imports, improve access to modern
therapeutic technologies, and strengthen the national pharmaceutical industry.
